By Dr. Benjamin Caplan, MD | Board-Certified Family Physician, CMO at CED Clinic | Evidence Watch
A 2025 clinical update in Indian Pediatrics consolidates randomized controlled trial evidence showing that purified cannabidiol (CBD) meaningfully reduces seizure frequency in children with Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. However, the review underscores that liver toxicity monitoring, significant drug interactions with clobazam and valproate, and the absence of rigorous data for artisanal CBD products all demand careful physician oversight before and during treatment.
CBD for Childhood Epilepsy: What the Evidence Actually Shows
A 2025 clinical update from a multinational author team reviews the landmark randomized controlled trials, approved dosing protocols, significant drug interactions, liver safety monitoring requirements, and remaining evidence gaps for cannabidiol therapy in pediatric drug-resistant epilepsy, including Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex.
#78
Strong Clinical Relevance
Directly summarizes FDA- and EMA-approved cannabinoid therapy with practical dosing and monitoring guidance for pediatric clinicians.
Pediatric Epilepsy
Drug-Resistant Seizures
Drug Interactions
Epidiolex
Drug-resistant epilepsy affects roughly one-third of children with epilepsy, and for syndromes like Dravet and Lennox-Gastaut, the search for additional effective therapies is urgent. Cannabidiol has moved from anecdotal use to a regulated pharmaceutical, yet clinicians outside specialized epilepsy centers may lack practical guidance on dosing thresholds, required laboratory monitoring, and the magnitude of drug interactions that change how co-administered anticonvulsants behave. This review addresses that knowledge gap at a moment when artisanal cannabis products are increasingly available to families, creating pressure on clinicians to differentiate between what is evidence-based and what is not.
Approximately 30% of children with epilepsy do not achieve seizure control with two or more appropriately chosen antiseizure medications, meeting the definition of drug-resistant epilepsy. Cannabidiol, the non-intoxicating major phytocannabinoid in cannabis, acts through mechanisms that remain incompletely understood but likely involve modulation of intracellular calcium, GPR55 signaling, adenosine reuptake, and TRPV1 channels rather than direct activity at CB1 or CB2 cannabinoid receptors. This 2025 narrative review by Whitney, Jauhari, and Jain synthesizes the pivotal randomized controlled trial data, open-label extension findings, and practical prescribing considerations for purified CBD (marketed as Epidiolex in the United States and Epidyolex in Europe) in the three syndromes for which it now holds regulatory approval: Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex.
The landmark RCTs reported median monthly seizure reductions of approximately 37 to 49% compared with placebo, with responder rates (defined as greater than 50% seizure reduction) reaching 36 to 49% depending on the trial and dose group. An open-label prospective trial of oral CBD titrated to 25 mg/kg/day in 137 patients aged 1 to 30 years showed a 36.5% median reduction in motor seizures and a 39% responder rate at 12 weeks. The review emphasizes that CBD triples plasma levels of N-demethylclobazam when co-administered with clobazam, and that concurrent valproate use raises hepatotoxicity risk, necessitating liver function testing at baseline and at 1, 3, and 6 months. The authors note that artisanal CBD-THC products showed observational responder rates comparable to purified CBD (37% vs. 42%) but with variable cannabinoid content and far less rigorous supporting evidence. They conclude that further research is needed for off-label epilepsy syndromes and for direct comparison of pharmaceutical and artisanal preparations.
This review does an excellent job of gathering the core RCT data into a readable format for generalists and pediatricians who may not follow epilepsy literature closely. The efficacy numbers are real and meaningful for these specific syndromes, and the dosing and monitoring protocols are clearly laid out. What the paper understandably cannot resolve is the gap between the tightly controlled pharmaceutical product and the artisanal CBD preparations that families are already using. Observational responder rates that look similar on paper obscure enormous differences in product consistency, cannabinoid ratios, and the absence of prospective safety monitoring in the artisanal space.
In my own practice, when families of children with refractory epilepsy ask about CBD, I start with their neurologist’s plan. If a pharmaceutical CBD product is accessible, that is the evidence-based path. When access or cost barriers lead families toward artisanal products, I insist on certificate-of-analysis documentation, start at the lowest plausible dose, and track liver enzymes and anticonvulsant levels just as rigorously as I would with Epidiolex. The clobazam interaction, in particular, catches families off guard, and I consider it the single most important safety point to communicate early.
This review arrives at a point where the regulatory arc for purified CBD in pediatric epilepsy is largely settled for the three approved indications. The Phase III trials that underpin FDA and EMA approval have been supplemented by open-label extension data showing sustained benefit and a consistent adverse effect profile over time. The remaining research frontier lies in establishing whether CBD has meaningful efficacy in other childhood epilepsy syndromes, in clarifying optimal dosing beyond the approved range, and in generating head-to-head data comparing pur
Have thoughts on this? Share it:
